Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics


Rubius Therapeutics, Inc. (RUBY)

Today's Latest Price: $5.20 USD

0.12 (2.36%)

Updated Aug 14 12:00am

Add RUBY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

RUBY Daily Price Range
RUBY 52-Week Price Range

RUBY Stock Price Chart Technical Analysis Charts


RUBY Price/Volume Stats

Current price $5.20 52-week high $14.44
Prev. close $5.08 52-week low $3.35
Day low $4.96 Volume 211,800
Day high $5.61 Avg. volume 342,953
50-day MA $5.90 Dividend yield N/A
200-day MA $7.24 Market Cap 419.99M

Rubius Therapeutics, Inc. (RUBY) Company Bio


Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.





RUBY Latest News Stream


Event/Time News Detail
Loading, please wait...

RUBY Latest Social Stream


Loading social stream, please wait...

View Full RUBY Social Stream

Latest RUBY News From Around the Web

Below are the latest news stories about Rubius Therapeutics Inc that investors may wish to consider to help them evaluate RUBY as an investment opportunity.

Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.

Yahoo | July 7, 2020

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Iveric Bio Goes Ahead with Second Pivotal Phase 3 Study of Zimura Iveric Bio (ISEE) announced that it has dosed the first patients for its second pivotal Phase 3 clinical trial GATHER2. The study seeks to evaluate Zimura’s potential for treating patients with geographic atrophy secondary to age-related macular degeneration....

Avisol Capital Partners on Seeking Alpha | July 2, 2020

Rubius Therapeutics updates on clinical progress of RTX-240 trial

Rubius Therapeutics (RUBY) has completed dosing of the first dose-escalation cohort with no observed adverse events to date in the Phase 1/2 clinical trial of RTX-240, an allogeneic cellular therapy for the treatment of patients with relapsed/refractory or locally advanced solid tumors.The Phase 1/2 trial of RTX-240 is evaluating the...

Seeking Alpha | June 30, 2020

Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition

Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it has completed dosing of the first dose-escalation cohort with no observed adverse events to date in the Phase 1/2 clinical trial of RTX-240. RTX-240 is an allogeneic cellular therapy for the treatment of patients with relapsed/refractory or locally advanced solid tumors. Rubius also announced a planned change to its management team.

Yahoo | June 30, 2020

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II

CAMBRIDGE, Mass., June 22, 2020 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to.

Yahoo | June 22, 2020

Read More 'RUBY' Stories Here

RUBY Price Returns

1-mo -12.90%
3-mo -7.14%
6-mo N/A
1-year -50.94%
3-year N/A
5-year N/A
YTD -45.26%
2019 -40.92%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7854 seconds.